Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), University Maastricht, Maastricht, The Netherlands.
Department of Hematology, Division of Internal Medicine, Maastricht UMC + , Maastricht, The Netherlands.
Thromb Haemost. 2023 Nov;123(11):1034-1041. doi: 10.1055/a-2101-7961. Epub 2023 May 26.
Hemophilia A (HA) is characterized by decreased or absent factor VIII (FVIII) activity. Current FVIII assays are based on clotting time and thus only provide information about the initiation of coagulation. In contrast, thrombin generation assays (TGAs) can be used to measure the full coagulation spectrum of initiation, propagation, and termination that provide information on the whole course of thrombin generation and inhibition. However, the commercially available TG kits lack sensitivity for measurements of hemophilia plasma within lower FVIII ranges, which is essential for explaining differences in bleeding phenotypes in hemophiliacs at clinically low levels of FVIII.
Optimization of the TGA for measurements of low FVIII levels in severe HA patients.
TGA measurements were performed in severe HA pooled plasma ( = 10). Investigations of several preanalytical and analytical variables of the assay were performed in a stepwise process and adjusted based on sensitivity toward intrinsic coagulation activation.
TGA initiated by tissue factor (TF) alone at varying concentrations was unable to significantly differentiate between FVIII levels below 20%. In contrast, TGA activation with low concentrations of TF in presence of FXIa appeared to be highly sensitive for FVIII changes both in high and low ranges. In addition, a representative TGA curve at trough levels could only be produced using the dual TF/FXIa TGA.
We propose a critical optimization for the setup of the TGA for measurements in severe HA plasma. The dual TF/FXIa TGA shows increased sensitivity, especially in lower FVIII ranges, which allows for better individual characterization at baseline, prediction of interventions, and follow-up.
血友病 A(HA)的特征是因子 VIII(FVIII)活性降低或缺失。目前的 FVIII 检测基于凝血时间,因此仅提供关于凝血起始的信息。相比之下,凝血酶生成检测(TGA)可用于测量启动、传播和终止的整个凝血谱,提供关于凝血酶生成和抑制全过程的信息。然而,商业上可用的 TGA 试剂盒在较低的 FVIII 范围内缺乏对血友病血浆测量的敏感性,这对于解释血友病患者在临床低 FVIII 水平下出血表型的差异至关重要。
优化 TGA 以测量严重 HA 患者的低 FVIII 水平。
在严重 HA 混合血浆中进行 TGA 测量( = 10)。在逐步过程中对检测的几个分析前和分析变量进行了研究,并根据对内在凝血激活的敏感性进行了调整。
单独使用组织因子(TF)启动的 TGA 无法在 FVIII 水平低于 20%时显著区分。相比之下,在低浓度 FXIa 存在下使用低浓度 TF 激活 TGA 似乎对高和低范围内的 FVIII 变化非常敏感。此外,仅使用双 TF/FXIa TGA 才能产生代表低谷水平的代表性 TGA 曲线。
我们提出了一种对严重 HA 血浆 TGA 测量的关键优化方案。双 TF/FXIa TGA 显示出更高的敏感性,特别是在较低的 FVIII 范围内,这允许在基线时进行更好的个体特征描述、干预预测和随访。